AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction
Complex lymphatic anomalies (CLA) can present with a spectrum of hematologic and systemic complications that are readily attributable to alternative diagnoses. We describe a child with type 2M VWD whose constellation of bleeding, splenomegaly, and hypogammaglobulinemia prompted years of extensive negative workup before CLA was considered, and empiric mTOR inhibition produced sustained remission.
Case Description
A 4-year-old male presented with 6 months of bruising, thrombocytopenia (33–36 × 10?/L), and splenomegaly (12.1 cm). PT/PTT were normal, Fibrinogen was not obtained. Workup revealed hypogammaglobulinemia (IgG 270–432 mg/dL) and established type 2M VWD: VWF:Ag 0.66–1.01 IU/mL, VWF:RCo 0.18–0.35 IU/mL (RCo/Ag 0.2–0.5), FVIII 41%–60%, normal multimer distribution, heterozygous VWF c.5191T>A (p.Ser1731Thr).
As these findings could not all be explained by VWD, evaluation over the next three years included two marrow evaluations showing megakaryocytic hyperplasia without malignancy, negative anti-platelet antibodies, and extensive immunodeficiency work up all without a unifying diagnosis. IVIG 1 g/kg was followed by a platelet fall from 51 to 22 × 10?/L within 48 hours. Four right knee hemarthroses after minimal trauma required VWF concentrate, with siderotic synovitis on MRI.
At age 7, fibrinogen was measured for the first time: 59 mg/dL, D-dimer 1.98 mg/L FEU. Fibrinogen then fell to <50 mg/dL with D-dimer 2.31 mg/L FEU. Correction after cryoprecipitate lasted less than 24 hours. Imaging showed numerous sharply defined sub-centimeter lytic lesions (spine, pelvis, ribs, sternum, extremities, clivus), splenomegaly to 14.7 cm, and retroperitoneal soft tissue thickening adjacent to the IVC and iliac vessels. PET showed no metabolically active disease. The combination of consumptive coagulopathy, splenomegaly, hypogammaglobulinemia, and lytic bone lesions ultimately raised strong clinical suspicion for an underlying vascular anomaly.
On this basis, empiric sirolimus was started following multidisciplinary review; systemic anticoagulation was considered but felt higher-risk given coexisting VWD. Within 4 weeks, fibrinogen rose from <50 to 140 mg/dL, platelets from 34 to 98 x 10?/L, and PTT normalized (41 to 32.7 s). At 18 months fibrinogen was ~200 mg/dL, platelets 167-276 x 10?/L, D-dimer 0.42-0.76 mg/L FEU, IgG in the 600s, and splenic length regressed from 14.7 to 11.1 cm, with resolution of severe bleeding. Sirolimus troughs were largely 3.8–8.3 ng/mL. Lymphangiography showed a dilated cisterna chyli and thoracic duct with impaired drainage into the central venous system, without hepatic, mesenteric, or renal reflux or pulmonary lymphatic perfusion- consistent with central conducting lymphatic anomaly. VANSeq panel of a core needle bone biopsy identified no pathogenic variant.
Discussion
VWF explained the mucocutaneous bleeding but not the thrombocytopenia, splenomegaly, or hypogammaglobulinemia, and these were extensively pursued. A vascular anomaly was not among the entities considered until well into the disease course. Several features indicated ongoing peripheral consumption: hemarthroses atypical for type 2M VWD, sub-24-hour correction after replacement, a paradoxical post-IVIG platelet fall, and megakaryocytic hyperplasia. Hypofibrinogenemia with elevated D-dimer defines severe LIC, reported in 6-10% of patients with slow-flow vascular malformations. Normal PT/PTT at presentation illustrates that standard coagulation screening does not exclude LIC, supporting first-tier fibrinogen and D-dimer in unexplained pediatric bleeding – particularly with cytopenias or organomegaly. The phenotype crosses the CLA spectrum: lytic bone lesions and retroperitoneal soft-tissue thickening favor generalized lymphatic anomaly/kaposiform lymphangiomatosis, while lymphangiography showed CCLA. Negative VANSeq panel does not exclude a somatic driver, given mosaicism and the limited tissue obtainable by core needle biopsy.
Conclusion
The combination of consumptive coagulopathy, splenomegaly, hypogammaglobulinemia, and lytic bone lesions should prompt evaluation for a CLA, even when some of these components are explained by an alternative existing diagnosis. Empiric sirolimus produced sustained hematologic and radiologic remission despite negative molecular testing, unavailable lesional histology, and troughs below conventional targets.
DISCLOSURES
Melanie Klemond, MD: No relevant conflicts of interest to declare.